PEOPLE - Bio-Technology General (US) makes appointment:
This article was originally published in Clinica
Executive Summary
Bio-Technology General (Iselin, New Jersey), a developer, manufacturer and marketer of genetically engineered and other products for healthcare, has appointed Christopher Clement as president and COO. Mr Clement, who most recently served as CEO and chairman at Epicyte Pharmaceutical, will replace Virgil Thompson, who vacated the position in 2000 but remains on the board.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.